{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:16:45Z","timestamp":1788675405069,"version":"build-2803163510"},"reference-count":11,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hypercalcemia of malignancy (HCM) occurs frequently in advanced stage cancer and can be secondary to many different etiologies. This case illustrates a rare case of dual-mediated PTH and osteolytic HCM in the setting of metastatic endometrial carcinoma. The patient's hypercalcemia was refractory to initial treatment with IV hydration, calcitonin, and zoledronic acid, eventually requiring the addition of denosumab therapy and cinacalcet. After 15 days of treatment, the patient's calcium concentration returned to normal levels. Owing to elevated PTH levels, other etiologies of hypercalcemia were not initially investigated. Bone metastases, which were not observed on admission computed tomography, were incidentally identified on the technetium-99\u2005m sestamibi scan. This case illustrates that although concurrent etiologies of hypercalcemia are uncommon, it is important to evaluate all possible contributing causes, especially in the clinical setting of malignancy.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf060","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T02:58:11Z","timestamp":1743389891000},"source":"Crossref","is-referenced-by-count":1,"title":["Dual-mediated PTH and Osteolytic Hypercalcemia in Metastatic Endometrial Carcinoma"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7671-331X","authenticated-orcid":false,"given":"Christine K","family":"Persaud","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Brooke Army Medical Center , Fort Sam Houston, TX 78234 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6376-2999","authenticated-orcid":false,"given":"Nicholas S","family":"Thorneloe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Brooke Army Medical Center , Fort Sam Houston, TX 78234 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary K","family":"Matthews","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Brooke Army Medical Center , Fort Sam Houston, TX 78234 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger S","family":"Gunther","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Brooke Army Medical Center , Fort Sam Houston, TX 78234 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0739-5618","authenticated-orcid":false,"given":"Darrick J","family":"Beckman","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Brooke Army Medical Center , Fort Sam Houston, TX 78234 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"5","key":"2025041110173919600_luaf060-B1","first-page":"496","article-title":"Hypercalcemia of malignancy","volume":"9","author":"Feldenzer","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"2025041110173919600_luaf060-B2","doi-asserted-by":"crossref","first-page":"1039490","DOI":"10.3389\/fendo.2023.1039490","article-title":"Cancer-related hypercalcemia and potential treatments","volume":"14","author":"Almuradova","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2025041110173919600_luaf060-B3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1210\/clinem\/dgac631","article-title":"A systematic review supporting the Endocrine Society clinical practice guideline on the treatment of hypercalcemia of malignancy in adults","volume":"108","author":"Seisa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025041110173919600_luaf060-B4","first-page":"e35783","article-title":"Treatment outcomes and survival in hypercalcemia of malignancy: a grave metabolic emergency","volume":"15","author":"Gupta","year":"2023","journal-title":"Cureus"},{"issue":"9","key":"2025041110173919600_luaf060-B5","first-page":"1959","article-title":"A practical approach to hypercalcemia","volume":"67","author":"Carroll","year":"2003","journal-title":"Am Fam Physician"},{"key":"2025041110173919600_luaf060-B6","author":"Davies"},{"issue":"2","key":"2025041110173919600_luaf060-B7","first-page":"e34770","article-title":"Malignant hypercalcemia induced by the ectopic production of intact parathyroid hormone (PTH)","volume":"15","author":"Neves","year":"2023","journal-title":"Cureus"},{"issue":"Supplement_1","key":"2025041110173919600_luaf060-B8","doi-asserted-by":"crossref","first-page":"SAT-494","DOI":"10.1210\/js.2019-SAT-494","article-title":"SAT-494 A very rare case: hypercalcemia caused by ectopic PTH secretion in endometrial cancer","volume":"3","author":"Batarseh","year":"2019","journal-title":"J Endocr Soc"},{"issue":"3","key":"2025041110173919600_luaf060-B9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/clinem\/dgac621","article-title":"Treatment of hypercalcemia of malignancy in adults: an endocrine society clinical practice guideline","volume":"108","author":"Fuleihan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 6","key":"2025041110173919600_luaf060-B10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0093-7754(01)90261-1","article-title":"Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program","volume":"28","author":"Major","year":"2001","journal-title":"Semin Oncol"},{"issue":"9","key":"2025041110173919600_luaf060-B11","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/5\/luaf060\/62791076\/luaf060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/5\/luaf060\/62791076\/luaf060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T10:27:07Z","timestamp":1744367227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf060\/8098706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,27]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf060","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,27]]},"article-number":"luaf060"}}